ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Vitamin B12 and pregabalin combination restored brain waves dynamics and behavior in chronic unpredictable mild stress (CUMS) model of depression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant late -life depression (TRLLD) is a major public health challenge, as older individuals present with suboptimal or partial responses to frontline therapeutic options. Chronic unpredictable mild stress (CUMS) is a well-validated preclinical paradigm that recapitulates the complex neurobiological changes and clinical symptomatology of major depression. Here, we elucidate the influence of pregabalin (PRG; 10 mg/kg) and vitamin B12 (B12; 40 µg/kg) combination on neurobiological correlates of LLD such as slow vs. fast brain rhythms, affective behavior, and oxidative stress in male C57BL/6 mice, aged 18 months. In the present study, we postulated that the modulation of oscillation synchronization in slow alpha and sleep spindle brainwaves with abnormal high beta oscillation synchronization is imperative to observed depressive-like phenotypes in CUMS-exposed mice, and this oscillatory pattern was absent in healthy control. Reciprocally, PRG + B12 combination restored thalamocortical coherence, as treated mice showed an increase in alpha (ɑ = 8.1 - 12 Hz) and sigma (Ʃ = 12.1 - 16 Hz) wave synchronization, while it reduced high beta rhythms (β = 24.1 - 30 Hz) bursting. Stressed geriatric mice exhibited reduced exploratory drive and impairments in proper cognition, while PRG + B12 chronic treatment mitigated the propagation of LLD-related behavioral dysfunction, as mice showed good performance in all conducted neurobehavioral assays (OFT, L/D, Y-maze, FST, and SPT). Furthermore, the PRG + B12 combination prompted redox homeostasis, as evidenced by reduced malondialdehyde (MDA) levels and increased antioxidant endogenous enzyme activity (superoxide dismutase; SOD and catalase; CAT). These outcomes support the use of multimodal network therapy to manipulate neurophysiological resilience in thalamocortical and corticocortical circuitry to modulate depression-like phenotypes and relapse in LLD patients.
Indexed as
Identifiers
42565846What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.